ArticleNPJ precision oncology2026
Organ-metastatic landscape delineates overall and site-specific immune-related adverse events of PD-L1 blockade in advanced NSCLC.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
It remains unknown whether metastases to different organs confer varying susceptibility to immune-related adverse events (irAEs) within a specific tumor type. We conducted a retrospective study included 708 advanced patients with non-small cell lung cancer (NSCLC) who received atezolizumab in two randomized controlled trials (OAK and POPLAR). Overall, irAEs were less frequent in patients with bone (OR = 0.52, p = 0.039) and pleural effusion metastases (OR = 0.65, p = 0.039), while more frequent in those with brain metastasis (OR = 1.96, p = 0.023). Cumulative irAEs risk differed significantly for patients with extra-thoracic (p = 0.034) but not intra-thoracic metastases (p = 0.680). In terms of site-specific irAEs, hepatitis, hypothyroidism, and rash were less frequent in patients with bone metastasis, whereas pneumonitis, adrenal insufficiency, and ocular inflammatory toxicity were more concentrated in patients with brain metastasis. A metastasis-based scoring system was developed by integrating the organ-metastatic landscape to identify high-risk populations for irAEs among NSCLC patients received PD-L1 blockade (p = 0.009). These findings highlight the predictive value of the organ-metastatic landscape for irAEs in advanced NSCLC received PD-L1 blockade.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.